GSK's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 numbers. Both turnover and EPS growth exceeded expectations, and the company's ...

EPS: UK£0.40 (up from UK£0.26 in 1Q 2024). We've discovered 4 warning signs about GSK. View them for free. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst ...

New study results with GSK's anti-IL-5 antibody Nucala in chronic obstructive pulmonary disease (COPD) have been published, just ahead of an FDA decision on the new indication scheduled for 7th May.

GSK is preparing to present data from its respiratory portfolio in more than 40 abstracts at the 2025 edition of the American Thoracic Society (ATS) International Congress, which will be held in San ...

Learn More. While the company’s long-term performance has lagged behind key rival AstraZeneca, recent momentum has ignited a degree of optimism that GSK may finally be turning a corner after ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

The basic lesson is that simplifying the system with understandable rates and principles should be fairer and more capable of achieving a strong foundation for funding our national government.

A groundbreaking new malaria vaccine that could be three times more effective than existing jabs is under development by scientists at GSK, the Telegraph can reveal. The product, earmarked for ...